Randomised phase-III-study of the multi-kinase inhibitors Sorafenib (BAY 43-9006) for patients with advanced renal cell carcinoma

被引：0
|
作者：
Staehler, M. [1 ]
Siebels, M. [2 ]
Stief, C. [1 ]
Jaeger, E.
Heinzer, H.
Grimm, M. -O.
Gschwend, J.
Wirth, M.
Michell, M. -S.
Rohde, D.
Krause, S.
Siegsmund, M.
Scheuring, U.
Schwartz, B.
Escudier, B.
机构：
[1] Univ Munich, Klin Grosshadern Ludwig Maximilians, Munich, Germany
[2] Urol Gemeinschaftspraxis Pasing, Munich, Germany
来源：
ONKOLOGE | 2007年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：18 / 19
页数：2
相关论文
共 50 条
  • [31] Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors
    Richly, H
    Henning, BF
    Kupsch, P
    Passarge, K
    Grubert, M
    Hilger, RA
    Christensen, O
    Brendel, E
    Schwartz, B
    Ludwig, M
    Flashar, C
    Voigtmann, R
    Scheulen, ME
    Seeber, S
    Strumberg, D
    ANNALS OF ONCOLOGY, 2006, 17 (05) : 866 - 873
  • [32] A phase II multicenter uncontrolled trial of single agent sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced non-small-cell lung carcinoma.
    Blumenschein, GR
    Gatzemeier, U
    Fossella, F
    Burk, K
    Reck, M
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9120S - 9120S
  • [33] A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401)
    Nabors, L. B.
    Rosenfeld, M.
    Chamberlain, M.
    Phuphanich, S.
    Batchelor, T.
    Supko, J.
    Desideri, S.
    Xiaobu, Y.
    Wright, J.
    Grossman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [34] Phase II study of bay 43-9006 (SORAFENIB) in patients with chemo-naive hormone refractory prostate cancer (HRPC)
    Chi, Kim N.
    Ellard, Susan
    Hotte, Sebastien J.
    Czaykowski, Piotr
    Moore, Malcolm
    Ruether, Joseph Dean
    Hansen, Clive
    Seymour, Lesley
    ANNALS OF ONCOLOGY, 2006, 17 : 152 - 152
  • [35] RETROSPECTIVE ANALYSIS OF THE SEQUENTIAL USE OF THE TWO MULTI-KINASE INHIBITORS, SORAFENIB AND SUNITINIB, IN PATIENTS (PTS) WITH ADVANCED RENAL CELL CARCINOMA (ARCC)
    Porta, Camillo
    Procopio, Giuseppe
    Carteni, Giacomo
    Sabbatini, Roberto
    Bearz, Alessandra
    Chiappino, Isabella
    Ruggeri, Enzo Maria
    Lo Re, Giovanni
    Landi, Lorenza
    Calcagno, Anna
    Imarisio, Ilaria
    Paglino, Chiara
    Verzoni, Elena
    Guadalupi, Valentina
    Rizzo, Mimma
    Canipari, Cinzia
    Bajetta, Emilio
    ANNALS OF ONCOLOGY, 2009, 20
  • [36] Final results of a phase I study of the Raf-1 kinase inhibitor BAY 43-9006 in patients with advanced refractory solid tumours
    Hirte, H
    Moore, M
    Hotte, S
    Oza, A
    Siu, L
    Harris, H
    MacLean, M
    Petrenciuc, O
    Fiander, W
    Lathia, C
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S55 - S55
  • [37] A clinical phase I and biomarker study of the Raf kinase inhibitor BAY 43-9006: preliminary evidence of activity in patients with advanced solid tumors
    Strumberg, D
    Voliotis, D
    Moeller, JG
    Hilger, RA
    Richly, H
    Beling, C
    Tewes, M
    Schleucher, N
    Scheulen, ME
    Seeber, S
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S53 - S54
  • [38] Phase II study of BAY 43-9006 using the randomized discontinuation design in patients with advanced refractory cancer.
    Ratain, MJ
    Stadler, W
    Smith, M
    Kindler, H
    O'Dwyer, P
    Flaherty, KT
    Kaye, S
    Xiong, H
    Eisen, T
    Patnaik, A
    Lee, RJ
    Lewis, J
    Schwartz, B
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6265S - 6266S
  • [39] Phase I study to determine the safety and pharmacokinetics of BAY 43-9006 in patients with advanced refractory solid tumors.
    Hirte, H
    Moore, MJ
    Oza, AM
    Siu, LL
    Harris, H
    Maclean, M
    Petrenciuc, O
    Fiander, W
    Lathia, C
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3768S - 3768S
  • [40] A phase II study of Sorafenib (BAY 43-9006) in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal cancer (NPC): final results
    Elser, C.
    Siu, L.
    Winquist, E.
    Agulnik, M.
    Pond, G.
    Chin, S.
    Francis, P.
    Cheiken, R.
    Petrenciuc, O.
    Chen, E.
    EJC SUPPLEMENTS, 2006, 4 (12): : 18 - 18
12345